Significance of intraprostatic architecture and regrowth velocity for considering discontinuation of dutasteride after combination therapy with an alpha blocker: A prospective, pilot study.
CONCLUSIONS: Prostatic enlargement after discontinuation of dutasteride differs among patients. Rapid regrowth of the prostate leads to deterioration of storage symptoms and a tendency to restart dutasteride. Baseline intraprostatic architecture may be a predictive factor for whether the patient is a good candidate for discontinuation.
PMID: 25874044 [PubMed - in process]
Source: Korean Journal of Urology - Category: Urology & Nephrology Tags: Korean J Urol Source Type: research
More News: Avodart | Benign Prostatic Hyperplasia | Overactive Bladder | Overactive Bladder Syndrome | Study | Ultrasound | Urology & Nephrology